Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0370220200640040334
Yakhak Hoeji
2020 Volume.64 No. 4 p.334 ~ p.342
Development of a Novel Dapagliflozin Orally Disintegrating Tablets
Kim Chul-Ho

Lee Seon-Ho
Kim Kyeong-Soo
Abstract
The purpose of this study is to develop a novel dapagliflozin orally disintegrating tablet (DF-ODT) to improvemedication compliance when administered orally for diabetics caused by chronic type 2. HPLC analytical method wasestablished for quantification of dapagliflozin L-proline, selected as a stable dapagliflozin cyrstalline salt form, then thephysicochemical properties and solubility were investigated. Various ODT formulations were prepared by using simplemixing and compression process. The effect of various excipients on tablet properties and impact of hardness on wettingand disintegrating time were investigated. Among the formulations tested, the formulation composed of dapagliflozin Lproline,Ludiflash¢ç, crospovidone, mint flavor powder, aspartame and Pruv¢ç at the weight ratio of 7.8/168.2/9/4/4/2 showedthe fastest wetting and disintegrating time with optimal hardness and friability. In addition, finally selected DF-ODTformulation showed the equivalence in the comparative dissolution test with Forxiga¢ç (dapagliflozin commercial product). Therefore, this DF-ODT could be a potential alternative to the dapagliflozin commercial product with increasedconvenience in treating type 2 diabetes.
KEYWORD
dapagliflozin L-priline, orally disintegrating tablet, disintegrating, dissolution
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)